Loading...
XSHE300206
Market cap833mUSD
Jan 10, Last price  
10.26CNY
1D
-3.02%
1Q
-1.91%
Jan 2017
8.00%
IPO
66.49%
Name

Edan Instruments Inc

Chart & Performance

D1W1MN
XSHE:300206 chart
P/E
27.62
P/S
3.15
EPS
0.37
Div Yield, %
1.96%
Shrs. gr., 5y
-0.18%
Rev. gr., 5y
14.32%
Revenues
1.94b
+11.22%
175,857,052228,922,673320,608,955375,294,090382,458,305454,607,048522,775,627550,136,390698,007,759843,277,974992,719,6261,136,243,0202,318,604,2311,636,411,0421,742,412,2981,937,988,917
Net income
221m
-5.00%
28,398,06245,906,52466,015,91059,185,78555,195,70234,702,86313,432,780103,209,22726,352,75443,766,98592,654,983131,850,513653,153,458231,436,439232,942,289221,301,109
CFO
154m
-54.06%
34,902,28147,878,61165,511,59544,101,25980,780,88330,125,8037,986,94928,451,8300113,960,81582,336,899115,288,444689,500,602237,283,290335,157,849153,961,216
Dividend
May 06, 20240.207 CNY/sh
Earnings
Apr 22, 2025

Profile

Edan Instruments, Inc. engages in the research, development, manufacture, and sale of medical equipment worldwide. The company offers diagnostic electrocardiograph (ECG) products, including resting ECG, stress test, holter, wireless solution, and ECG workstation products; patient monitoring systems, such as vital signs, transport, and central monitoring systems, as well as high acuity cares, acute and sub-acute cares, telemetry, and pulse oximetry products; and obstetrics and gynecology products comprising fetal and maternal monitoring systems, fetal telemetry systems, ultrasonic doppler systems, and video colposcopes. It also provides ultrasound imaging systems that include color doppler ultrasound and B/W digital ultrasound systems; and in-vitro diagnostics, which comprise hematology analyzers. In addition, the company offers point-of-care testing systems, including blood gas and chemistry, magnetic immunoassay, and colloidal gold-labeled immunoassay analyzers; and veterinary ultrasound, ECG, ABG, and monitoring products. Edan Instruments, Inc. is headquartered in Shenzhen, the People's Republic of China.
IPO date
Apr 21, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,937,989
11.22%
1,742,412
6.48%
Cost of revenue
1,389,733
1,472,975
Unusual Expense (Income)
NOPBT
548,256
269,437
NOPBT Margin
28.29%
15.46%
Operating Taxes
(128)
11,171
Tax Rate
4.15%
NOPAT
548,384
258,266
Net income
221,301
-5.00%
232,942
0.65%
Dividends
(119,990)
(119,990)
Dividend yield
2.03%
1.72%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
5,211
Long-term debt
22,180
10,375
Deferred revenue
21,047
21,573
Other long-term liabilities
1
2
Net debt
(966,703)
(988,294)
Cash flow
Cash from operating activities
153,961
335,158
CAPEX
(51,096)
Cash from investing activities
(48,029)
64,197
Cash from financing activities
FCF
391,294
302,242
Balance
Cash
941,711
957,004
Long term investments
47,173
46,876
Excess cash
891,984
916,760
Stockholders' equity
1,700,407
1,588,327
Invested Capital
1,104,026
947,384
ROIC
53.46%
25.63%
ROCE
27.44%
14.43%
EV
Common stock shares outstanding
579,683
579,683
Price
10.21
-15.13%
12.03
-14.56%
Market cap
5,918,567
-15.13%
6,973,591
-14.29%
EV
4,951,864
5,985,297
EBITDA
601,277
324,330
EV/EBITDA
8.24
18.45
Interest
2,040
1,581
Interest/NOPBT
0.37%
0.59%